Keriann Cherofsky, an executive at IQVIA Holdings Inc. (NYSE:IQV), sold 558 shares on July 29, 2026, for a total value of about $136,827, according to an SEC Form 4 filing.
Transaction summary
Key questions
What is the remaining scale of direct ownership for the executive?
Following the disposition of 558 shares, the insider maintains a direct equity position of 2,989 shares, which carries a market valuation of $739,956.84 based on the July 29, 2026 market close.How does the execution price compare to recent market levels?
The shares were sold at $245.21 per share, while the stock was priced at $237.82 as of the July 30, 2026 market close, reflecting the recent valuation of the $38.8 billion healthcare diagnostics company.What is the broader operational context for the issuing company?
IQVIA Holdings operates as a global provider of analytics and clinical research services, reporting trailing twelve-month revenue of $17.0 billion and net income of $1.4 billion as of the transaction period.
Company Overview
Company Snapshot
IQVIA provides sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services to the life sciences industry through three primary operating segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The company generates revenue through a diversified business model that combines data analytics, technology platforms, clinical trial services, and sales force outsourcing solutions for pharmaceutical, biotechnology, and medical device manufacturers globally.
IQVIA serves pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare organizations across the Americas, Europe, Africa, and Asia-Pacific regions, positioning itself as a critical partner in drug development and commercialization.
IQVIA Holdings Inc. is a premier global provider of life sciences intelligence and services with employees operating across multiple continents. The company maintains a competitive advantage through its integrated platform combining proprietary data, advanced analytics, and extensive clinical research capabilities, enabling clients to optimize drug development timelines and commercialization strategies. With TTM revenue of $17.0 billion and a market capitalization of $38.8 billion, IQVIA has demonstrated strong market positioning and sustained growth momentum, evidenced by a one-year share price appreciation of 27.25%.
